The results of this trial are expected to provide preliminary data on the short-term effects and feasibility of non-ablative radiofrequency therapy combined with PFMT as a non-invasive therapeutic option for GSM in breast cancer survivors.
Lázaro-Navas et al. (Sat,) studied this question.